As reported by the National Health Executive, a new artificial intelligence system could help clinicians choose more effective antidepressants for individual patients, potentially improving treatment outcomes for people with depression, researchers say
The tool, known as PETRUSHKA, analyses a range of personal information to predict which antidepressant is most likely to work for a specific patient. It considers factors such as clinical history, demographic characteristics and individual concerns about possible side effects.
Scientists say the system is designed to support shared decision making, allowing patients and clinicians to discuss treatment options with clearer evidence about which medication may be most suitable.
The technology was developed by researchers at the University of Oxford with support from the National Institute for Health and Care Research through a Research Professorship. Additional backing came from the NIHR Oxford Health Biomedical Research Centre and the NIHR Applied Research Collaboration Oxford and Thames Valley.
Results from the research, published in the Journal of the American Medical Association, suggest the approach could improve several aspects of treatment. Patients whose medication was selected using the system were:
• More likely to show improvements in depression and anxiety symptoms after 24 weeks
• About 40% less likely to stop treatment during the first eight weeks
• Less likely to discontinue medication because of side effects
• More likely to experience improved mental health outcomes over six months
Researchers say these findings indicate the tool could help address some of the most common challenges in antidepressant treatment, including early discontinuation and inconsistent response to medication.
Be the first to comment